Company profile
Oxford BioTherapeutics
Redefining the cancer-immune synapse for novel immune checkpoint mechanisms
- Industry
- Biotechnology
- Employees
- 72
- Headquarters
- Oxford
- Founded
- 2004
- Office locations
- 3
Oxford BioTherapeutics company summary
Oxford BioTherapeutics is a company in the Biotechnology industry, headquartered in Oxford, founded in 2004. On LinkedIn the company has around 72 employees. The company lists 3 office locations. Its listed specialties include Cancer, Biotechnology, Oncology, Proteomics, Protein Target Discovery.
What technology does Oxford BioTherapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).
Specialties
Where is Oxford BioTherapeutics located?
Oxford BioTherapeutics lists 3 office locations.
Compare companies similar to Oxford BioTherapeutics
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Oxford BioTherapeutics oxfordbiotherapeutics.com | Biotechnology | 72 | 2004 | Oxford |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about Oxford BioTherapeutics
What does Oxford BioTherapeutics do?
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).
How many employees does Oxford BioTherapeutics have?
Oxford BioTherapeutics has around 72 employees on LinkedIn.
Where is Oxford BioTherapeutics headquartered?
Oxford BioTherapeutics is headquartered in Oxford.
Where does Oxford BioTherapeutics have offices?
Oxford BioTherapeutics lists 3 office locations, including Oxford, OX4 4GE, GB; Morristown, New Jersey, US; San Jose, California, US.
When was Oxford BioTherapeutics founded?
Oxford BioTherapeutics was founded in 2004.
Build a lead list from companies like Oxford BioTherapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.